Background and Aims: Capsule endoscopy [CE] and magnetic resonance enterography [MRE] are prime modalities for evaluation of the small bowel in Crohn's disease [CD]. Detection of proximal small bowel [SB] inflammation in CD by MRE is challenging. Currently available quantitative MRE scores do not incorporate proximal SB data. The MRE global score [MEGS] was designed for quantitative evaluation of the entire digestive tract; its accuracy in the proximal SB has not previously been evaluated. This study compared the evaluation of the small bowel inflammation by MEGS and CE-derived quantitative score (the Lewis score [LS] Conclusions: MEGS provides accurate evaluation of the SB and strongly correlates with FC; the main advantage of MEGS is the accurate quantification of proximal SB inflammation unavailable for alternative MRE scores.
Introduction
The treatment paradigm in Crohn's disease [CD] has shifted from treating/abolishing symptoms towards reducing inflammatory activity and achieving mucosal healing. The new treatment paradigm has been repeatedly demonstrated to be associated with improved disease course and reduction of long-term complications. [1] [2] [3] CD involves the small bowel [SB] in the majority of patients, and is limited to the SB in about 30% of them. 4 SB inflammation is frequently proximal to the terminal ileum and thus inaccessible to conventional ileocolonoscopy. 5 Magnetic resonance enterography [MRE] and capsule endoscopy [CE] are both leading modalities for SB assessment of patients with suspected or established CD. 6 The diagnostic yield of CE is superior to that of computed enterography, ileocolonoscopy and SB follow-through 7 and comparable to that of MRE. 8, 9 Although the overall diagnostic accuracy of the two modalities is similar, CE appears to be more sensitive for detection of proximal [duodenum/ jejunum/proximal ileum] inflammation. 10 CE can detect previously unknown proximal SB inflammation in at least 50% of the patients with established CD. 11 Proximal SB disease is of significant prognostic merit as patients with active proximal disease on CE tend to have a more aggressive disease and faster progress to surgery. 5 Detection of proximal inflammation on MRE is challenging [ Figure 1 ], mainly due to inadequate delineation of mucosal ulceration and difficulty in obtaining adequate distention of the proximal SB. 12 Most currently available quantitative inflammation scores for MRE such as MaRIA [Magnetic Resonance Index of Activity] score or the diffusion weighted [DW-MRE] based Clermont index were validated and correlated only with disease in the terminal ileum and the colon and do not attempt to evaluate proximal inflammation. 13, 14 SB inflammation on CE can be quantified using two diagnostic scores, the Lewis score [LS] 15 and capsule endoscopy Crohn's disease activity index [CECDAI] . 16 Both scores were recently validated for monitoring of inflammatory activity in the SB. 17, 18 The magnetic resonance enterography global score [MEGS] was developed to quantify panenteric disease burden and includes both longitudinal disease extent and extra-enteric findings. 19, 20 MEGS was shown to significantly correlate with faecal calprotectin [FC] levels and ileocolonoscopic findings 20 and was used in both newly diagnosed and established CD patients in both adult and paediatric cohorts. [19] [20] [21] MEGS decreased significantly in clinical responders to anti-tumour necrosis factor α [TNF-α] therapy but not in non-responders, demonstrating moderate correlation with clinical disease activity. 19 MEGS does not rely on identification of mucosal ulceration, a potential advantage for proximal SB disease.
Therefore, MEGS may potentially be the most appropriate MRE-based inflammatory score for evaluation of the proximal SB. However, the accuracy of MEGS has not been validated in the proximal SB as none of the existing studies used an accurate comparator modality for proximal SB disease. Validation of a panenteric score will require a comparison with another panenteric modality with a clearly established and validated quantitative scoring system. Upon validation, this score may have a valuable advantage for future clinical studies in CD in comparison with previously described scores that do not quantify findings proximal to the distal ileum. CE provides an accurate and comprehensive evaluation of the entire length of the SB. The LS 15 divides the small bowel into three tertiles and assigns points to various findings [mucosal oedema, ulcers, strictures] characteristic for CD in each of the tertiles, incorporating the severity and the extent of each finding into the score. The tertile score represents the most severe finding in this tertile, while the most severely involved tertile produces the final score. 22 Our previous studies have demonstrated a moderate correlation between the MaRIA and Clermont scores with the LS. 23, 24 The aim of the current study was to evaluate the utility of MEGS for quantitative assessment of small bowel inflammation.
Methods

Patient population
The current study was a retrospective analysis of prospectively collected data, as part of a larger project aimed to identify predictors of clinical relapse in quiescent CD patients. 25 The study population included adult [>18 years] CD patients with established SB disease in clinical remission (Crohn's disease activity index [CDAI] < 150) that were in corticosteroid-free remission for 3-24 months and treated with a stable medication dose (60 days for thiopurines and methotrexate and infliximab, 30 days for adalimumab and 5-aminosalicylic acid [5-ASA) agents). All patients signed an informed consent form and the study was approved by the institutional ethics review board of the Sheba Medical Center.
MRE examinations
A 1.5T GE Optima MR450w scanner with GEM Suite [GE Healthcare] was used for all MRE examinations using a previously described protocol [25] [26] [27] [28] [29] [30] [ Table 1 ]. Oral and intravenous contrast materials were administered to all the patients. The oral contrast was 360 ml of Osmitrol 20% diluted in water to obtain 1.5 litres of solution. Oral contrast was divided into four portions, given every 15 min 1 h before the MRE examination. During the last 15 min, the patients received a slow intra-venous infusion of 150 ml of saline containing 0.5 mg of glucagon. Liver Acquisition with Volume 
MRE interpretation
Two MRE quantitative scores were calculated: MEGS and the MaRIA score.
The MEGS was calculated for the entire alimentary tract [jejunum to rectum] and the MaRIA score was calculated for the distal SB, defined as the distal 20 cm of the terminal ileum.
The MEGS was calculated using the MEGS formula as described in Table 2. 19-21,31 Score per segment was calculated for the following segments: jejunum, ileum, terminal ileum, caecum, ascending, transverse, descending, sigmoid and rectum. Jejunum was defined as bowel with a feathery fold pattern to the left of a diagonal drawn from the right upper quadrant to the left lower quadrant on a coronal image. Ileum was defined as the SB to the right of this line and terminal ileum as the 30 cm of ileum immediately proximal to the ileocecal valve.
Each segmental MRE feature is scored from 0 to 3. The length of the diseased segment is used to provide a multiplication factor [ranging from 1 to 2] for the summation of each segmental score. Individual segmental scores are added together, and then five points are added for each extra-mural feature. Thus, the total MEGS = [jejunal score × factor for jejunum 
Capsule endoscopy studies
A patency capsule [PC] test was performed in all patients with active SB disease detected on MRE. If no active SB disease was detected by MRE, a PC study was not performed. As suggested by the manufacturer if a PC was not eliminated from the SB within 30 h, the patient was withdrawn from the study. In patients with isolated SB CD, an SB-III capsule [Given Imaging] was used. In patients with established ileo-colonic CD, a colonic capsule [PillCam 2 colonic capsule, Given Imaging] was administered. When a colonic capsule was used, the SB data were reviewed and analysed similarly to the procedure for the SB capsule. All images were reviewed using the RAPID 8 software [Given Imaging]; the reader was blinded to MRE results with the exclusion of the cases without active SB disease in order to decide on the need for PC testing. Mucosal inflammation was quantified using the LS. 15 Mucosal healing was defined as LS < 135, mild to moderate inflammation as LS of 135-790, and moderate to severe inflammation as LS > 790. 15 In addition to the traditional LS that is derived from the highest score achieved by one of the SB tertiles, we calculated the cumulative Lewis score [C-LS] by summation of the individual tertile scores. Proximal SB was defined as the first and the second tertiles in accordance with SB transit times. When a colonic capsule was used, LS was calculated manually. 
Inflammatory biomarkers
Statistical analysis
Descriptive statistics were presented as means ± standard deviations for continuous variables and percentages for categorical variables. Categorical variables were analysed by chi square/Fisher's exact test and continuous variables by Student's t-test/Mann-Whitney test as appropriate. We performed a Pearson correlation analysis for correlation of both total and segmental CE and MRE scores with each other and with FC levels. Correlation r values < 0.3 were considered as weak-to-low correlation, 0.3-0.49 as low-to-moderate, 0.5-0.69 as moderate and ≥0.7 as strong correlation. 35 Linear regression was performed to identify the MEGS values that correspond to the segmental LS cut-off values of 135 and 790. A two-tailed p value < 0.05 was considered statistically significant. The analysis was performed using IBM SPSS statistic [Version 20.0].
Results
Fifty patients were included in the final analysis. The clinical characteristics of the patients are detailed in Table 3 . All patients were in clinical remission and none had active perianal disease upon enrollment. On CE, the first tertile was involved in 26 Table 5 ].
Correlation between modality scores
Median MEGS was significantly different in patients with proximal LS < 135, 135 ≤ LS < 790 and LS > 790, respectively. In the distal SB [ Figure 2 ] and the entire SB, median MEGS was significantly higher in patients with LS > 790; no significant differences were demonstrated between patients with mucosal healing and mild inflammation [ Figure 2 ]. Scatterplots demonstrating the correlation between the scores are presented in Figure 3 . The outliers included patients with stenosed segments detected by both MRE and MEGS, as such segments yield substantially higher LS values in comparison with any other inflammation feature. 15 Next, we performed a linear regression to identify segmental MEGS values that correspond to the accepted LS cut-off values [LS < 135 for mucosal healing; LS ≥ 790 for moderate to severe inflammation]. For the proximal SB, MEGS < 2.6 corresponded to LS < 135 and MEGS > 5.9 corresponded to LS ≥ 790. In the distal SB, MEGS < 3.6 corresponded to LS < 135 and MEGS > 6.9 corresponded to LS ≥ 790.
Discussion
Our study demonstrated that MEGS significantly correlates with mucosal inflammation as assessed by CE. MEGS was designed for quantification of pan-intestinal inflammatory burden and has an important potential advantage in providing quantification of the proximal SB inflammation. Other quantitative MRE scores such as MaRIA, Clermont and Nancy scores do not address the proximal SB and were validated against ileocolonoscopy. 36 Another advantage of the MEGS is that it also takes into account extraluminal findings that do not contribute to the other scores. MEGS has not yet been evaluated endoscopically, as such validation requires a pan-intestinal endoscopic tool [CE] as a comparator. For CE, there is a well-established quantitative scoring system for inflammation [LS] that was validated for both suspected and established CD. 15, 18 Interestingly, the original LS is not a cumulative score as it comprises the highest score produced by any of the three SB tertiles. When we used the LS as a cumulative score [summation of the score of all three tertiles] the correlation with MEGS [also a cumulative score] was further improved. Moreover, the correlation with FC, which is a surrogate of the panenteric inflammatory burden, 22, 25, 37 was also stronger for the cumulative scores. In the present study the correlation of MEGS with FC was even stronger than reported originally. 20 In the distal SB, the performance of both MRE scores tested was very similar, with a strong correlation between the two.
The most important finding was the reasonable correlation between the quantitative assessment of proximal SB inflammation by CE and MEGS. MEGS was able to distinguish patients with mucosal healing from those with active inflammation in the proximal SB, and to identify patients with moderate to severe inflammations. Overall, MRE tends to underestimate the prevalence of proximal SB involvement, which can be detected in at least 50% of CD patients by CE and significantly less by MRE. 10, 11, 38 Proximal SB involvement in CD as demonstrated by CE is associated with a more aggressive disease course and an increased need for surgery. 5, 39 Our study is the first to provide endoscopic validation for an MRE-based inflammation score. Note, however, that the two modalities assess different aspects of the disease -CE evaluates mucosal inflammation while disregarding intraluminal changes and extraluminal findings, while MRE is oriented towards intramural findings [wall thickness, oedema, stratification, etc.] and extraluminal manifestations. Those do not necessarily coexist in every given patient and bowel segment. 40, 41 While the concept of mucosal healing is well established in CD, with an abundance of data pointing to improved short-and long-term outcomes in patients achieving mucosal healing, 3 the concept of 'transmural' healing as assessed by cross-sectional imaging remains significantly less well established. [41] [42] [43] [44] A recent study that utilized computed enterography and MRE for follow-up of CD patients starting treatment demonstrated that radiological 45 improvement was associated with less corticosteroid use, and decreased rates of hospitalizations and surgery. 46 It is well established that clinical activity scores correlate poorly with active inflammation in CD. 45 In the majority of patients who are in stable clinical remission, active inflammation can be detected by MRE and CE. 25 Nevertheless, clinical criteria still guide our treatment decisions, not only in clinical practice but also in selection of patients for clinical trials, universally leading to exclusion of patients who could have benefited from treatment due to undetected active disease and inclusion of symptomatic patients with negligible inflammatory burden. 40, 47 Although endoscopic evaluation is almost ultimately required in modern IBD trials, ileocolonoscopy may frequently underestimate the disease burden, or miss it completely if the inflammation is proximal to the terminal ileum. Procedural risk and patient discomfort, which frequently discourage eligible patients from participation, should also be considered. Panenteric evaluation with CE 48 or MRE 49 is feasible within the framework of a clinical trial, and may provide comprehensive and quantitative insight into the patient's inflammatory burden, with repeated evaluation to access achievement of the therapeutic goals. Our study indicates that MEGS is an appropriate quantitative tool for this purpose due to its capacity to provide complete quantitative evaluation of the digestive tract and its significant correlation with FC as a surrogate marker of the inflammatory burden. Cross-sectional evaluation will also allow for prospective monitoring of structural damage using quantitative tools such as the Lemann index. 28, [50] [51] [52] [53] [54] Our study has several limitations. Primarily, all of our patients were in clinical remission and on stable treatment and we did apply our study question to patients with clinically active disease. Nevertheless, a vast majority of our patients had detectable endoscopic inflammation. Previous work from our group has demonstrated better correlation between MRE scores and LS in endoscopically active patients and patients with elevated FC. 23, 24 Moreover, MEGS was demonstrated to be sensitive to changes in the inflammatory burden in clinically active patients starting anti-TNF therapy. 19 Although it is likely that in clinically active patients the correlation might be even stronger than in the current study, the generalizability of our results to clinically active patients needs further evaluation in additional studies.
An additional limitation stems from the difficulty in comparing the exact anatomical parts between the capsule and MRE. On the present CE software [Rapid 8, Medtronic], the SB segments are defined by the transition time from pylorus to caecum. Transit speed is not constant and the capsule can be quickly propelled forward in certain segments and stalled in others. On MRE, the segments are established by their quadrant location. Neither technique is precise and correlation between the methods has not been established. Finally, MEGS, just as with other quantitative MRE scores, is time-consuming, cumbersome and not easy to use in daily practice. In summary, our study provides an endoscopic validation of MEGS and suggests that it has significant merits for quantitative assessment of SB inflammation in CD by providing panenteric evaluation and accurate assessment of the inflammatory burden.
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